[Trial of interruption of antiparkinson drugs in long term treatments with neuroleptics]

Abstract

The authors by placebo methods interrupted the antiparkinsonian treatment in chronic psychotic patients who had a neuroleptic treatment for at least three months. Three weeks after: 72 percent had to receive the antiparkinsonian they took before, in consequence of extrapyramidal manifestations (an half of the sample receive this antiparkinsonian during the first week), and more than a third presented an acute psychotic outbreak. However, 28 percent of the total sample were still with placebo. Authors are questioning the psychotropic activity of antiparkinsonians, the influence of neuroleptic doses and the specificity of each administred neuroleptic. They conclude in opposition with other authors, to the necessity of prescribing continuously antiparkinsonians in most of the cases of chronic psychoses, in long-term neuroleptic treatment.